Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Zogenix A Good Stock To Buy Now?

RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX). A new filing with the U.S. Securities and Exchange Commission revealed that RA Capital holds 1.84 million shares of Zogenix, Inc (NASDAQ:ZGNX). The stake represents 7.5% of the company’s common stock, and is passive by nature.

Peter Kolchinsky

Boston-based RA Capital, founded by Peter Kolchinsky in 2001, focuses on healthcare and life-sciences companies. The fund invests in companies with promising drugs and technologies. It offers private, IPO, and follow-on financing for its portfolio companies to enable management teams to drive value creation without facing capital shortages from inception through product commercialization. RA Capital’s most recent 13F filing showed that the fund manages a public equity portfolio worth $994.11 million.

Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 118% since then and outperformed the S&P 500 Index by around 60 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

Zogenix Inc (NASDAQ:ZGNX) is a pharmaceutical company engaged in the development of therapies for the treatment of central nervous system (CNS) disorders. The company has a market cap of $257.54 million. Zogenix Inc (NASDAQ:ZGNX) raised $98.33 million in proceeds from a public offering, which was completed in August. The offering included about 5.46 million common shares, with 712,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares were offered at a price of $18.00 a share.

Follow Zogenix Inc. (NASDAQ:ZGNX)
Trade (NASDAQ:ZGNX) Now!

Last month, Zogenix Inc (NASDAQ:ZGNX) announced positive top-line pharmacokinetic results from its phase 1b multi-dose clinical trial of Relday, which is a once-monthly subcutaneous investigational formulation of risperidone, for the treatment of schizophrenia. The company believes that Relday, which is subject to approval, has the potential to be the first subcutaneous antipsychotic product that allows for once-monthly dosing and achieves therapeutic drug levels on the first day of administration. In a statement, Zogenix Inc (NASDAQ:ZGNX) said that the phase 1b multi-dose clinical trial for Relday was conducted as a single-center, open-label, safety and PK trial of 60 patients with chronic, stable schizophrenia or schizoaffective disorder across a dose range of 60, 90 and 120 mg, and included a comparator arm of Risperdal Consta. Zogenix Inc (NASDAQ:ZGNX) is now starting efforts to secure a global strategic development and commercialization partner for Relday.

On the next page, we’ll talk about the company’s stock and its financial performance.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.